期刊
EUROPEAN UROLOGY
卷 45, 期 6, 页码 706-713出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eururo.2003.03.001
关键词
erectile dysfunction; MT-II; MC4 receptor; oxytocin; pharmacotherapy; central regulation
Objective: Review the historical and current evidence that suggests that activation of melanocortin receptors modulates erectile activity. Methods: The available literature was reviewed. Results: Melanocortin peptides derived from the pro-opiomelanocortin (POMC) precursor protein exert a host of diverse physiological effects in the periphery and in the CNS through interactions with one or more of the five cloned melanocortin receptors. Natural and synthetic melanocortin peptide agonists influence erectile and sexual function in a range of preclinical species. Emerging clinical evidence now suggests that the proerectile effects observed in preclinical species are evident in man as well. Conclusions: Preclinical and clinical results support the involvement of melanocortins in the modulation of erectile and sexual function. Current evidence indicates that the melanocortin 4 receptor subtype contributes to the proerectile effects observed with pan-receptor agonists. However, the putative receptor subtypes, pathways and mechanisms implicated in mediating the proerectile effects of melanocortins remain to be fully elucidated. (C) 2004 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据